I am writing about the article called "CT screening for lung cancer: Update 2007," which appeared in the January 2008 issue of The Oncologist [1] . The article contains numerous problematic and unsubstantiated assertions, in many cases inappropriately coupled to references that are either unrelated to, or contradictory to the point made by the authors.
UNDER "KEY CONCEPTS AND DEFINITIONS"
1. The authors tell readers that the staging system for lung cancer "is based on differences in lung cancer survival." Their reference is to the update on lung cancer staging by Mountain, which states that the lung cancer staging system is based on identifying the intersection of similar treatment options and similar outcome expectations [2] .
2. The authors present the term "curability rate," although it has no concrete meaning in epidemiology. Their reference is to Martini and colleagues, where the concept of "curability rate" does not appear [3] .
3. The authors present, in Figure 1 , estimates of "cure rates," a concept that is not found in conventional epidemiology. They cite as their source for the cure rate estimates the "American Cancer Society Facts and Figures: 2006 ." Yet, no cure rates appear in that report.
4. The authors claim that there is a distinction between "baseline" and "subsequent" rounds of screening. They cite Morrison [4] . In that article, no such distinction appears. In fact, Morrison focuses on a hypothetical scenario in which only a single round of screening (i.e., only the baseline round) has been performed.
5. The authors assert that "length bias" only affects the first round of screening, again referencing Morrison [4] . Morrison's article explicitly contradicts the authors on this point, noting that length bias cannot be sequestered to certain patients in a single-arm noncomparative design (such as Early Lung Cancer Action Project [ELCAP]). The Morrison article more generally critiques the type of design pursued by ELCAP, while implicitly endorsing randomized trials such as the National Lung Screening Trial (NLST). He states that "the observed case-fatality (the ELCAP endpoint) is not an appropriate measure of the beneficial effect of screening. Outcome evaluation of a screening programme is best carried out by comparison of mortality rates in the screened population with those in another otherwise comparable unscreened population (i.e., the NLST design)."
UNDER "THE EARLY LUNG CANCER ACTION PROJECT APPROACH"
1. The authors assert that for "curability determination, a comparison group may be formed by randomly assigning people with screen-diagnosed lung cancer to immediate or delayed treatment, as was done for prostate cancer" [5] . Yet, the study they reference did not randomize individuals after screening detection, but instead randomized patients found to have prostate cancer by a variety of means [6] . 3. The authors claim that the cumulative mortality rate declined in years 5 and 6 of a study examining computed tomography screening [7] . The study referenced contains no such finding. In that study, the cumulative number of events over time (i.e., deaths from lung cancer), not the cumulative mortality rate, was examined.
UNDER "CONCERNS ABOUT THE I-ELCAP APPROACH"
1. The authors assert that lead time and length time biases affect both the ELCAP and randomized trials of screening, providing four references. Two references are to letters the authors have written, and are thus circular. The other two are to Morrison [4] and Hanley [8] ; this assertion appears nowhere in either. In fact, in Hanley [8] , neither the term "lead time" nor the term "length time" is even discussedthat article focuses on a subtle point regarding the analysis of comparative screening studies where the endpoint is the mortality rate (as in the NLST) [8] .
2. The authors report that, in I-ELCAP, "those who were in stage I who had no treatment all died from lung cancer," referencing their own work [9] . As noted by Yee and Lynch, the cause of death of these eight subjects was not specified in the paper that the authors reference [10] .
On a potentially related point, the authors state that Figure 11 displays a comparison of individuals who did and did not receive treatment for their lung cancer. The graph leaves open some questions. For instance, if these data are meant to reflect the outcomes of the 8 untreated subjects the authors have frequently referenced in their publications, then why are there 13, not 8, events in the untreated group? Also, why is there no censoring in the untreated group (as evidenced by the fact that there are equal size steps and no tick marks in the Kaplan-Meier curve), while over the same period of follow-up, there is abundant censoring among the group of treated subjects? It would be helpful to readers if the authors would address these questions, and more generally describe the sources of data used to construct the two curves in this figure.
The evaluation of cancer screening approaches is complex, and involves many subtle epidemiologic concepts that can seem counterintuitive.
